The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Cited by (622)

Items 201–300 of 622

1. Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints
   Yi Wen Kong, Erik C. Dreaden, Sandra Morandell, Wen Zhou, Sanjeev S. Dhara, Ganapathy Sriram, Fred C. Lam, Jesse Christopher Patterson, Mohiuddin Quadir, Anh Dinh et al. · 2020 · Nature Communications
2. Myelodysplastic syndrome: An inability to appropriately respond to damaged DNA?
   Zhou, Ting, Hasty, Paul, Walter, Christi A., Bishop, Alexander J.R., Scott, Linda M., Rebel, Vivienne I. · 2013 · Experimental Hematology
3. Proteomics insights into DNA damage response and translating this knowledge to clinical strategies
   Louise von Stechow, Jesper V. Olsen · 2016 · PROTEOMICS
4. MDTips: a multimodal-data-based drug–target interaction prediction system fusing knowledge, gene expression profile, and structural data
   Xiaoqiong Xia, Chaoyu Zhu, Fan Zhong, Lei Liu · 2023 · Bioinformatics
5. Chemotherapy-induced acetylation of ACLY by NAT10 promotes its nuclear accumulation and acetyl-CoA production to drive chemoresistance in hepatocellular carcinoma
   Yuying Wang, Kunqi Su, Chang Wang, Tao Deng, Xiaofeng Liu, Shiqi Sun, Yang Jiang, Chunfeng Zhang, Baocai Xing, Xiaojuan Du · 2024 · Cell Death and Disease
6. Lactylation of XLF promotes non-homologous end-joining repair and chemoresistance in cancer
   Mingpeng Jin, Bingsong Huang, Xiaoning Yang, Shuyang Wang, Jinhuan Wu, Yiming He, Xin Ding, Xuanhe Wang, Zhe Wang, Jie Yang et al. · 2025 · Molecular Cell
7. Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers
   Chongkui Sun, Fan Zhang, Tao Xiang, Qianming Chen, Tej K. Pandita, Yuping Huang, Mickey C.‐T. Hu, Qin Yang · 2014 · Oncotarget
8. SALL4 promotes glycolysis and chromatin remodeling via modulating HP1α-Glut1 pathway
   J. Kim, Shi Xu, Lingyun Xiong, Lili Yu, Xuemei Fu, Yang Xu · 2017 · Oncogene
9. DNA Damage Repair System in Plants: A Worldwide Research Update
   Estela Giménez, Francisco Rogelio Manzano-Agugliaro · 2017 · Genes
10. Resting T cells are hypersensitive to DNA damage due to defective DNA repair pathway
    Qian Hu, Yujie Xie, Yuanlong Ge, Xin Nie, Jun Tao, Yong Bo Zhao · 2018 · Cell Death and Disease
11. DNA Damage/Repair Management in Cancers
    Jehad F. Alhmoud, John F. Woolley, Ala‐Eddin Al Moustafa, Mohammed Imad Mallei · 2021
12. The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer
    Liangliang Ren, Xingrong Qing, Jihong Wei, Haixin Mo, Yuanji Liu, Yaofeng Zhi, Wenjie Lu, Mingzhu Zheng, Weijian Zhang, Yuan Chen et al. · 2023 · Cell Death and Disease
13. Opportunities and hurdles in the treatment of BRCA1-related breast cancer
    Rinske Drost, Jos Jonkers · 2013 · Oncogene
14. Evolving insights: how DNA repair pathways impact cancer evolution
    Jiadong Zhou, Xiao Albert Zhou, Ning Zhang, Jiadong Wang · 2020 · Cancer Biology and Medicine
15. Induction of DNA damage and ATF3 by retigeric acid B, a novel topoisomerase II inhibitor, promotes apoptosis in prostate cancer cells
    Yongqing Liu, Fengbin Gao, Hanming Jiang, Leilei Niu, Yiling Bi, Charles Y.F. Young, Huiqing Yuan, Hong‐Xiang Lou · 2013 · Cancer Letters
16. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
    Jack Carter, Michael Hulse, Monisha Sivakumar, Jessica Burtell, Venkat Thodima, Min Wang, Anjana Agarwal, Komali Vykuntam, Jacob Spruance, Neha Bhagwat et al. · 2023 · Cancer Research Communications
17. Metabolic Features of Cancer Treatment Resistance
    Andrea Viale, Giulio Francesco Draetta · 2016 · Recent results in cancer research/Recent Results in Cancer Research
18. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia
    Na Li, Michael A. Lopez, María Linares, Subodh Kumar, Stefania Oliva, Joaquín Martínez‐López, Lian Xu, Yan Xu, Tommaso Perini, William T. Senapedis et al. · 2018 · Clinical Cancer Research
19. Recent progress in H 2 S activated diagnosis and treatment agents
    Xiaodong Wang, Lu An, Qiwei Tian, Kuili Cui · 2019 · RSC Advances
20. A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway
    Andrew F. Voter, Kelly A. Manthei, James L. Keck · 2016 · SLAS DISCOVERY
21. Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells
    Yi Liao, Xiaojia Niu, Bailing Chen, Holly J. Edwards, Liping Xu, Chengzhi Xie, Hai Lin, Lisa Polin, Jeffrey Warren Taub, Yubin Ge et al. · 2016 · Journal of Medicinal Chemistry
22. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
    Domenica Lorusso, Elisa Tripodi, Giuseppa Maltese, Stefano Lepori, Ilaria Sabatucci, Giorgio Bogani, Francesco Raspagliesi · 2018 · Drug Design Development and Therapy
23. Targeted therapies in gynaecological cancers
    Shanthini Mary Crusz, Rowan E. Miller · 2019 · Histopathology
24. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy
    İbrahim Halil Şahin, Christine A. Iacobuzio–Donahue, Eileen Mary O'Reilly · 2015 · Expert Opinion on Therapeutic Targets
25. VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells
    Elena Navarro-Carrasco, Pedro A. Lazo · 2021 · Frontiers in Cell and Developmental Biology
26. Targeting cancer drug resistance utilizing organoid technology
    Changpeng Chai, Pengfei Ji, Hao Xu, Huan Tang, Zhengfeng Wang, Hui Zhang, Wence Zhou · 2022 · Biomedicine & Pharmacotherapy
27. Regulation of DNA damage responses and cell cycle progression by hMOB2
    Valentí Gómez, Ramazan Gündoğdu, Marta Gómez-Ferrer, Lily Hoa, Neelam Panchal, Mark O’Driscoll, Alexander Hergovich · 2014 · Cellular Signalling
28. Reversing Cancer Multidrug Resistance in Xenograft Models via Orchestrating Multiple Actions of Functional Mesoporous Silica Nanoparticles
    Debin Yang, Tingfang Wang, Zhigui Su, Lingjing Xue, Ran Mo, Can Zhang · 2016 · ACS Applied Materials & Interfaces
29. The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis
    Mari I. Suominen, Timothy Wilson, Sanna-Maria Käkönen, Arne Scholz · 2019 · International Journal of Molecular Sciences
30. Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology
    Robert Klopfleisch, Barbara Kohn, Achim Dieter Gruber · 2015 · The Veterinary Journal
31. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
    Jiayan Luo, Juan Jin, Fang Yang, Zijia Sun, Wenwen Zhang, Yaqin Shi, Jing Xu, Xiaoxiang Guan · 2016 · International Journal of Biological Sciences
32. Recent progress of hydrogel-based local drug delivery systems for postoperative radiotherapy
    Yandong Xie, Mingxi Liu, Chang Chun Cai, Chengkun Ye, Tangjun Guo, Kun Yang, Hong Xiao, Xianglong Tang, Hongyi Liu · 2023 · Frontiers in Oncology
33. Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair
    Michael P. Croglio, Jefferson M. Haake, Colin P. Ryan, Victor S. Wang, Jennifer Lapier, Jamie P. Schlarbaum, Yaron Dayani, Emma Artuso, Cristina Prandi, Hinanit Koltai et al. · 2016 · Oncotarget
34. Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance
    Xiaxia Niu, Ting Wu, Gege Li, Xinsheng Gu, Yanan Tian, Hongmei Cui · 2021 · International Journal of Biological Sciences
35. GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells
    Fang Li, Qinyun Xia, Lian Ren, Yuhong Nie, He Ren, Xiaoyu Guo, Jinqiang Yu, Yiqiao Xing, Zhen Chen · 2022 · Oxidative Medicine and Cellular Longevity
36. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer
    Ching‐Chia Li, Juan‐Cheng Yang, Mei‐Chin Lu, Chia-Lin Lee, Chieh-Yu Peng, Wei-Yu Hsu, Yun-Hao Dai, Fang‐Rong Chang, Da-yong Zhang, Wen‐Jeng Wu et al. · 2015 · Oncotarget
37. Extracellular Matrix Characterization in Gastric Cancer Helps to Predict Prognosis and Chemotherapy Response
    Zhi Yang, Feifei S. Xue, Minhuan Li, Xingya Zhu, Xiaofeng Lu, Chao Wang, En Xu, Xingzhou Wang, Liang Zhang, Yu Heng et al. · 2021 · Frontiers in Oncology
38. Adaptor SH3BGRL drives autophagy-mediated chemoresistance through promoting PIK3C3 translation and ATG12 stability in breast cancers
    Shaoyang Zhang, Xiufeng Liu, Saleh Abdulmomen Ali Mohammed, Hui Li, Wanhua Cai, Wen xian Guan, Daiyun Liu, Yanli Wei, Dade Rong, Ying Fang et al. · 2021 · Autophagy
39. The evidence for repurposing anti-epileptic drugs to target cancer
    Mir Aroosa, Jonaid Ahmad Malik, Sakeel Ahmed, Onur Bender, Nafees Ahemad, Sirajudheen Anwar · 2023 · Molecular Biology Reports
40. 4EGI-1 targets breast cancer stem cells by selective inhibition of translation that persists in CSC maintenance, proliferation and metastasis
    Tingfang Yi, Eihab Kabha, Evangelos Papadopoulos, Gerhard Wagner · 2014 · Oncotarget
41. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer
    Ah‐Rong Nam, Mei Hua Jin, Ji Eun Park, Ju‐Hee Bang, Do‐Youn Oh, Yung‐Jue Bang · 2018 · Cancer Research and Treatment
42. Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review
    Zhe‐Sheng Chen, Lizhu Lin, Sheng-Xiong Zhang, Wei Liu, Bo Ai, Lingling Sun · 2021 · Recent Patents on Anti-Cancer Drug Discovery
43. The DNA damage response: The omics era and its impact
    Kasper Derks, Jan H.J. Hoeijmakers, Joris Pothof · 2014 · DNA repair
44. ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis
    Vinod Vijay Subhash, Shi Hui Tan, Mei Shi Yeo, Fui Leng Yan, Praveen C. Peethala, Natalia L. M. Liem, Vaidehi Krishnan, Wei Peng Yong · 2016 · Molecular Cancer Therapeutics
45. Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
    Rowan E. Miller, Osnat Elyashiv, Karim Hussien El-Shakankery, Jonathan Andrew Ledermann · 2022 · OncoTargets and Therapy
46. Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer
    Manuela La Montagna, L. H. GINN, Michela Garofalo · 2020 · Cancer Gene Therapy
47. Prediction of Overall Survival Among Female Patients With Breast Cancer Using a Prognostic Signature Based on 8 DNA Repair–Related Genes
    Dai Zhang, Si Yang, Yiche Li, Jia Yao, Jian Ruan, Yi Zheng, Yujiao Deng, Na Li, Bajin Wei, Ying Wu et al. · 2020 · JAMA Network Open
48. Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy
    Kerry Silva McPherson, Dmitry M. Korzhnev · 2021 · RSC Chemical Biology
49. RECQL1 and WRN DNA repair helicases: potential therapeutic targets and proliferative markers against cancers
    Kazunobu Futami, Yasuhiro Furuichi · 2015 · Frontiers in Genetics
50. Targeting BRG1 Chromatin Remodeler via Its Bromodomain for Enhanced Tumor Cell Radiosensitivity In Vitro and In Vivo
    Su-Jung Kwon, Seulki Lee, Juri Na, Shin-Ai Lee, Han-Sae Lee, Ji‐Hye Park, June‐Key Chung, Hyewon Youn, Jongbum Kwon · 2014 · Molecular Cancer Therapeutics
51. Evolution of genetic instability in heterogeneous tumors
    Ani Davitovna Asatryan, Natalia L. Komarova · 2016 · Journal of Theoretical Biology
52. Crosslinked Chitosan‐PEG Hydrogel for Culture of Human Glioblastoma Cell Spheroids and Drug Screening
    Fei‐Chien Chang, Sheeny K. Lan Levengood, Nick Cho, Likai Chen, Everet Wang, John S. Yu, Miqin Zhang · 2018 · Advanced Therapeutics
53. Chromatin damage generated by DNA intercalators leads to degradation of RNA Polymerase II
    Jaime A Espinoza, Dimitris C. Kanellis, Sheetanshu Saproo, Karla Leal, Johana Fernández Martínez, J. Bartek, M. Lindström · 2024 · Nucleic Acids Research
54. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity
    Rui Xie, Yan Li, Pingwah Tang, Qipeng Yuan · 2017 · Bioorganic & Medicinal Chemistry Letters
55. Breviscapine (BVP) inhibits prostate cancer progression through damaging DNA by minichromosome maintenance protein-7 (MCM-7) modulation
    Yangbo Guan, Dongrong Yang, Shao-jun Nong, Jian Ni, Chunhui Hu, Jian Li, Jin Zhu, Yu-xi Shan · 2017 · Biomedicine & Pharmacotherapy
56. Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers
    Mehdi Sanati, Christian G. Figueroa‐Espada, Emily Laura Han, Michael J. Mitchell, Saber Amin Yavari · 2024 · ACS Nano
57. miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells
    Zheng Wang, Hao Yin, Yuanwei Zhang, Yukun Feng, Zhaofeng Yan, Xiaohua Jiang, Ihtisham Bukhari, Furhan Iqbal, Howard J. Cooke, Qinghua Shi · 2014 · Cell Cycle
58. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment
    Laura Ren Huey Ip, George Poulogiannis, Felipe Cia, Junko Sasaki, Satoshi Kofuji, Victoria J. Spanswick, Daniel Hochhauser, John Anthony Hartley, Takehiko Sasaki, Christina Anja Gewinner · 2015 · Oncotarget
59. Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy
    Daniela A. Dungl, Elaina N. Maginn, Euan A. Stronach · 2015 · Frontiers in Oncology
60. Long Term Aggresome Accumulation Leads to DNA Damage, p53-dependent Cell Cycle Arrest, and Steric Interference in Mitosis
    Meng Lü, Chiara Boschetti, Alan Tunnacliffe · 2015 · Journal of Biological Chemistry
61. Therapeutic Nanocarriers via Cholesterol Directed Self-Assembly of Well-Defined Linear-Dendritic Polymeric Amphiphiles
    Oliver C. J. Andrén, Yuning Zhang, Pontus Lundberg, Craig J. Hawker, Andreas M. Nyström, Michael Malkoch · 2017 · Chemistry of Materials
62. miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer
    Kha Wai Hon, Nadiah Abu, Nurul‐Syakima Ab Mutalib, Rahman A Jamal · 2018 · Frontiers in Pharmacology
63. The APEX1/miRNA-27a-5p axis plays key roles in progression, metastasis and targeted chemotherapy of gastric cancer
    Huimin He, Fengying Song, Qian Gao, Zheng Lu, Yue Yuan, Xinyao Li, Lirong Chen, Chenshuang Jia, Ruina Yang, Jin Ping Yang et al. · 2021 · International Journal of Pharmaceutics
64. Impacts of cancer therapy on male fertility: Past and present
    Kathleen Duffin, Rod Thomas Mitchell, Mark F. H. Brougham, Geert Hamer, Ans M. M. van Pelt, Callista L. Mulder · 2024 · Molecular Aspects of Medicine
65. Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model
    Benjamin Lemasson, Hanxiao Wang, Stefanie Galbán, Yinghua Li, Yuan Zhu, Kevin Heist, Christina Tsein, Thomas L. Chenevert, Alnawaz Rehemtulla, Craig J. Galbán et al. · 2016 · Neoplasia
66. Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target
    Liliana Raimundo, Juliana Calheiros, Lucı́lia Saraiva · 2021 · Cancers
67. Multifunctional Nanoparticles Improve Therapeutic Effect for Breast Cancer by Simultaneously Antagonizing Multiple Mechanisms of Multidrug Resistance
    Qi Yin, Jianan Shen, Zhiwen Zhang, Haijun Yu, Lingli Chen, Wangwen Gu, Yaping Li · 2013 · Biomacromolecules
68. Molecular mechanisms of sensitivity and resistance to radiotherapy
    Jessica L. Xing, Baldassarre Stea · 2024 · Clinical & Experimental Metastasis
69. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks
    Jun Dong, Tian Zhang, Yufeng Ren, Zhenyu Wang, Clifton C. Ling, Fuqiu He, Gloria C. Li, Chengtao Wang, Bixiu Wen · 2017 · Oncotarget
70. Amplification of TLK2 Induces Genomic Instability via Impairing the G2–M Checkpoint
    Jin-Ah Kim, Meenakshi Anurag, Jamunarani Veeraraghavan, Rachel Schiff, Kaiyi Li, Xiao‐Song Wang · 2016 · Molecular Cancer Research
71. Precision medicine based on tumorigenic signaling pathways for triple‑negative breast cancer (Review)
    Nan Wu, Jinghua Zhang, Jing Zhao, Kun Mu, Jun Zhang, Zhao Jin, Jinpu Yu, Juntian Liu · 2018 · Oncology Letters
72. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells
    Makoto Takeuchi, Michihiro Tanikawa, Kazunori Nagasaka, Katsutoshi Oda, Yoshiko Kawata, Shinya Oki, Agapiti H Chuwa, Kenbun Sone, Yuko Miyagawa, Haruko Hiraike et al. · 2019 · Cancers
73. NKX6.1 Represses Tumorigenesis, Metastasis, and Chemoresistance in Colorectal Cancer
    Hsin-Hua Chung, Chun‐Te Lee, Je‐Ming Hu, Yu‐Ching Chou, Ya‐Wen Lin, Yu‐Lueng Shih · 2020 · International Journal of Molecular Sciences
74. Understanding the DNA double-strand break repair and its therapeutic implications
    Ujjayinee Ray, Sathees C. Raghavan · 2021 · DNA repair
75. Targeting the DNA Damage Response Machinery for Lung Cancer Treatment
    Katharigatta Narayanaswamy Venugopala · 2022 · Pharmaceuticals
76. Cytotoxicity of the bisphenolic honokiol from Magnolia officinalis against multiple drug-resistant tumor cells as determined by pharmacogenomics and molecular docking
    Mohamed E.M. Saeed, Victor Kuete, Onat Kadioglu, Jonas Börtzler, Hassan Khalid, Henry Johannes Greten, Thomas Efferth · 2014 · Phytomedicine
77. Methuosis Inducer SGI‐1027 Cooperates with Everolimus to Promote Apoptosis and Pyroptosis by Triggering Lysosomal Membrane Permeability in Renal Cancer
    Yu Luo, Bing Guan, Xiaoqi Deng, Peide Bai, Haichao Huang, Chaohao Miao, Anran Sun, Zhipeng Li, Dianqiang Yang, Xuegang Wang et al. · 2024 · Advanced Science
78. IL‐36γ and IL‐36Ra Reciprocally Regulate NSCLC Progression by Modulating GSH Homeostasis and Oxidative Stress‐Induced Cell Death
    Peng Wang, Wei Zhong Yang, Hao Guo, Hong‐Peng Dong, Yu‐Yao Guo, Hu Gan, Zou Wang, Yongbo Cheng, Yu Deng, Shi-Zhe Xie et al. · 2021 · Advanced Science
79. Managing Cancer Drug Resistance from the Perspective of Inflammation
    Shuaijun Lu, Yang Li, Changling Zhu, Weihua Wang, Yuping Zhou · 2022 · Journal of Oncology
80. Preparation of a paclitaxel-loaded cationic nanoemulsome and its biodistribution via direct intratumoral injection
    Yurui Xu, Sajid Asghar, Hongying Li, Minglei Chen, Zhigui Su, Yangfan Xu, Qineng Neng Ping, Yanyu Xiao · 2016 · Colloids and Surfaces B Biointerfaces
81. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells
    Józefa Węsierska‐Gądek, Matthias Mauritz, Goran Mitulović, Maria Cupo · 2015 · Journal of Cellular Biochemistry
82. The E3 ligase APC/C Cdh1 promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth
    Juxiang Cao, Xiangpeng Dai, Lixin Wan, Hongshen Wang, Jinfang Zhang, Philip S. Goff, Elena V. Sviderskaya, Zhenyu Xuan, Zhixiang Xu, Xiaowei Xu et al. · 2015 · Science Signaling
83. The biology and treatment of leiomyosarcomas
    William G. J. Kerrison, Khin Thway, Robin L. Jones, Paul H. Huang · 2023 · Critical Reviews in Oncology/Hematology
84. Syk-dependent alternative homologous recombination activation promotes cancer resistance to DNA targeted therapy
    Qin Zhou, Xinyi Tu, Xiaonan Hou, Jia Yu, Fei Zhao, Jinzhou Huang, Jake A. Kloeber, Anna Olson, Ming Gao, Kuntian Luo et al. · 2023 · Drug Resistance Updates
85. Post-Transcriptional Up-Regulation of PDGF-C by HuR in Advanced and Stressed Breast Cancer
    Nianan Luo, Yaqi Qu, Guodong Yang, Tao Wang, Renli Li, Lintao Jia, Rui Dong · 2014 · International Journal of Molecular Sciences
86. Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer.
    Ming-Hui Xue, Guang-Yan Li, Xin-Jun Wu, Chao-Xian Zhang, Cai-Feng Zhang, Kong-Xi Zhu · 2015 · PubMed Central
87. Peptide Hormone Regulation of DNA Damage Responses
    Vera Chesnokova, Shlomo K. Melmed · 2020 · Endocrine Reviews
88. HSATII RNA is induced via a noncanonical ATM-regulated DNA damage response pathway and promotes tumor cell proliferation and movement
    Nogalski, Maciej T., Shenk, Thomas · 2020 · Proceedings of the National Academy of Sciences
89. A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer
    Ke Ding, Youhua He, Jinfen Wei, Shuying Fu, Jiajian Wang, Zixi Chen, Haibo Zhang, Yimo Qu, Keying Liang, Xiaocheng Gong et al. · 2022 · Frontiers in Immunology
90. Multifunctional nanoparticles for trimodal photodynamic therapy-mediated photothermal and chemotherapeutic effects
    Raju Vivek, Varukattu Nipun Babu, Chandrababu Rejeeth, Sharma Alok, Thondhi Ponraj, Alagarsamy Vasanthakumar, Soundarapandian Kannan · 2018 · Photodiagnosis and Photodynamic Therapy
91. Bleomycin induces senescence and repression of DNA repair via downregulation of Rad51
    Fuqiang Chen, Wenna Zhao, Chenghong Du, Zihan Chen, Jie Du, Meijuan Zhou · 2024 · Molecular Medicine
92. Optimization of pyrazole/1,2,4-triazole as dual EGFR/COX-2 inhibitors: Design, synthesis, anticancer potential, apoptosis induction and cell cycle analysis
    Nesma M. Kahk, Fatma E.A. Mohamed, Marwa M. Abdelhakeem, Rania B. Bakr · 2025 · European Journal of Medicinal Chemistry
93. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R
    TING XIONG, Heng Wei, XIAOQIONG CHEN, Hui Xiao · 2014 · International Journal of Oncology
94. Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway
    Jingjing Zhang, Jingchun Zhou, Shuifang Xiao · 2020 · Anti-Cancer Drugs
95. Molecular Profiling of Exceptional Responders to Cancer Therapy
    Marijo Bilušić, Daniel M. Girardi, Yan Zhou, Kyungsuk Jung, Jianming Pei, Michael J. Slifker, Qingrong Chen, Daoud M. Meerzaman, Katherine R. Alpaugh, Denise Young et al. · 2020 · The Oncologist
96. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance
    Zhigang Wang, Zoufeng Xu, Guangyu Zhu · 2016 · Angewandte Chemie
97. Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer
    Nami Yamashita, Atsushi Fushimi, Yoshihiro Morimoto, Atrayee Bhattacharya, Masayuki Hagiwara, Masaaki Yamamoto, Tsuyoshi Hata, Geoffrey Ira Shapiro, Mark D. Long, Song Liu et al. · 2022 · Cancers
98. Expression of SRPK1 in gliomas and its role in glioma cell lines viability
    Ioanna Sigala, Konstantinos Ioannis Tsamis, Anna Gousia, George Α. Alexiou, Spyridon Voulgaris, Thomas Giannakouŕos, Athanassios P. Kyritsis, Eleni Nikolakaki · 2016 · Tumor Biology
99. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells
    Makoto Isono, Kazuki Okubo, Takako Asano, Akinori Sato · 2021 · Scientific Reports
100. RAD51AP1 Loss Attenuates Colorectal Cancer Stem Cell Renewal and Sensitizes to Chemotherapy
     Allison E. Bridges, Sabarish Ramachandran, Kavin Tamizhmani, Utkarsh Parwal, Adrienne Lester, Pragya Rajpurohit, Daley S. Morera, Sarrah L. Hasanali, Pachiappan Arjunan, Ravirajsinh N. Jedeja et al. · 2021 · Molecular Cancer Research